Current status and future prospects of subcutaneous immunotherapy―including SCIT with birch pollen extract―

DOI Web Site 17 References

Bibliographic Information

Other Title
  • 皮下免疫療法の現状と今後の展望 (白樺花粉を含めて)

Search this article

Description

<p> Allergen immunotherapy is the only radical treatment for allergic diseases, and in recent years, its effectiveness and clinical significance have been re-acknowledged. In particular, sublingual immunotherapy (SLIT) has become prevalent in recent years ; in light of its safety and convenience, SLIT is expected to form a central part of immunotherapy. Currently, however, due in part to the fact that it is indicated only for those aged 12 years and older and that there are only two types of antigens treated―house dust mites and Japanese cedar―subcutaneous immunotherapy (SCIT) remains a critically important means of treatment. Nonetheless, SCIT also still has numerous issues. In terms of safety, in particular, there is a high incidence of systemic symptoms, and it is hoped that safer formulations can be developed, or safer up-dosing schedules can be established. Another important issue is that far fewer allergen extracts are available for use in Japan as compared to abroad. As one treatment with future potential, our department has been implementing SCIT with birch pollen extract against pollen-food allergy syndrome (PFAS), with favorable results.</p>

Journal

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top